2021年6月18日,辉瑞公司在MAbs期刊发表了GUCY2C/CD3双特异性抗体PF-07062119的研究文章“Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors”[1]。该研究提示,在食蟹猴体内,靶向GUCY2C/CD3双抗表现出显著的抗肿瘤活性。早在去年,PF-07062119临...
产品名称 Research Grade Anti-Human GUCY2C & CD3E Bispecific Antibody (PF-07062119) 产品货号 DHD65603 产品别名 Bispecific 表达系统 Mammalian Cells 靶标 STAR, Intestinal guanylate cyclase, GC-C, GUC2C, STA receptor, Heat-stable enterotoxin receptor, Guanylyl cyclase C, hSTAR, GUCY2C, T3E, T...
GUCY2c is a tumor target expressed in >90% of colorectal cancer (CRC). It is also expressed on the apical side of intestinal epithelial tight junctions, where it regulates intestinal fluidity. PF-07062119, a GUCY2c-CD3 bispecific antibody that recruits T cells to GUCY2c expressing ...
事实上,已有早期临床试验表明,在甲状腺癌或结肠直肠癌患者中,GUCY2C CAR-T治疗显著抑制了肿瘤生长,其疗效显著。基于GUCY2C的免疫治疗,早前辉瑞的GUCY2C/CD3双特异性抗体PF-07062119临床前研究结果就已证实,GUCY2C在结直肠癌(CRC)中的抗肿瘤活性,且毒性可控。此外,PF-07062119与抗PD-1/PD-L1治疗联合使用,可...
[3]Mathur D1,Root AR2,Bugaj-Gaweda B3, et al. A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers[J]. Clin Cancer Res ,2020, DOI:10.1158/1078-0432. [4] Snook A E , Baybutt T R , Xiang B , et al. Split tolerance...
PF-07062119 is a T cell engaging bispecific antibody that binds to CD3 and guanylyl cyclase C, a protein that is over-expressed by colorectal cancers. Here, we used 89Zr-Df-IAB22M2C (89Zr-Df-Crefmirlimab), a human CD8-specific minibody to monitor CD8+ T cell infiltration into tumors ...
The methods of producing the antibody and bispecific antibody are also disclosed.;EFFECT: obtaining new antibodies with high affinity for GUCY2 and CD3.;36 cl, 38 dwg, 49 tbl, 35 ex
Additionally, to address immune evasion mechanisms, combinations of the GUCY2C-CD3 bispecific are explored with immune checkpoint blockade therapy, as well as with chemotherapeutic and anti-angiogenic agents that could enhance immune infiltration into tumors. Our preclinical in vivo data demonstrate that...